Introduction
Efficacy and safety of TCZ, an IL-6 receptor inhibitor, were previously demonstrated at wk 40 of CHERISH, a phase 3 trial in patients (pts) with pcJIA [1] .
Objectives
To investigate efficacy and safety of TCZ over 104 wks of treatment in pcJIA.
Methods
Pts 2-17 years old with ≥6 months' active pcJIA who failed methotrexate received open-label (OL) TCZ (weight ≥30 kg, 8 mg/kg [n = 119]; weight <30 kg, randomised [1:1] to 8 [n = 34] or 10 [n = 35] mg/kg) every 4 wks for 16 wks. Pts with ≥JIA ACR30 response at wk 16 entered a 24-wk double-blind withdrawal period and were randomised (1:1) to placebo or continuation with TCZ. Pts with JIA ACR30 flare or who completed the withdrawal period entered an OL extension through wk 104.
Results
188 pts entered the lead-in period, 166 entered the withdrawal period, 160 entered the OL extension period and 155 completed 104 wks. In pts who received TCZ throughout the study, JIA ACR responses and improvement in JIA ACR core components (Table) were maintained through wk 104. The safety population comprised 188 pts with 307 pt years (PY). Rates/100PY of AEs and serious AEs (SAEs) were 406.5 and 11.1, respectively; infections were the most common AE (151.4) and SAE (5.2). ALT and AST elevations ≥3 × upper limit of normal occurred in 6.4% and 2.7% of pts, respectively. Grade 3 neutropenia and grade 2/3/4 thrombocytopenia occurred in 5.9% and 1.6% of pts, respectively. LDL cholesterol ≥110 mg/dl occurred in 16.2% of pts.
Conclusion
Efficacy of TCZ was maintained through 2 years of treatment in pts with pcJIA, with no change in safety profile from that reported previously [1] .
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